High materiality8/10
Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Cantor Fitzgerald raises VRTX target to 595 from 590; current price 470.72.
- Cantor Fitzgerald raises VRTX target to 595 (from 590).
Key facts
- 01
Target: $595
- 02
Posted price: $470.72
- 03
Analyst firm: Cantor Fitzgerald
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.